CHM 1101 (CLTX CAR T) DATA ACCEPTED FOR PRESENTATION AT SOCIETY...

CHM 1101 (CLTX CAR T) DATA ACCEPTED FOR PRESENTATION AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

"Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to highlight the acceptance of two CHM 1101 (CLTX CAR T) abstract presentations at the Society for Neuro-Oncology (SNO) 26th annual scientific meeting being held from November 18-21, 2021. The inclusion of these abstracts in the premier global neuro-oncology meeting recognizes the importance of the development of CHM 1101 (CLTX CAR T) to the field of neuro-oncology drug development. Clinical evaluation of the initial dose cohort in the phase 1 clinical trial for CHM 1101 (CLTX CAR T) will be presented on Friday, November 19 within abstract CTIM-29. This abstract presentation will provide new information on the safety, efficacy, and bioactivity of CHM 1101 in patients treated at the initial low dose level of 44 X 106 cells with intratumoral administration in the ongoing phase 1 clinical trial. Commenting on what the Company is looking for from the information to be presented at SNO, Chimeric’s CEO and Managing Director Jennifer Chow said: “These data are critical to advancing our clinical development program. At the low dose level that patients in this cohort received, we are focused on being able to establish safety and bioactivity in patients. Once we are able to further characterize the safety and bioactivity of CHM 1101, we will be able to move forward to focus on our exploration of efficacy at the higher dose levels in the trial with dual routes of administration.” Abstract EXTH-10, to be presented on Friday November 19, will provide further insight into the mechanism by which CHM 1101 (CLTX CAR T) recognizes glioblastoma tumor cells. These novel findings continue to advance Chimeric’s understanding of the precise composition and localization of the cell surface complex recognized by CLTX CAR T. Acceptance of these abstracts for presentation at the 26th annual SNO meeting requires an embargo on all CHM 1101 clinical data until the online abstract release on November 11, 2021. Details of the abstract presentations are as follows: Abstract #:CTIM-29 Abstract Title: Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastomaPresentation Date:Friday November 19, 2021 Abstract #:EXTH-10 Abstract Title: Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognize glioblastoma cells? Presentation Date:Friday November 19, 2021" As the above says: " Acceptance of these abstracts for presentation at the 26th annual SNO meeting requires an embargo on all CHM 1101 clinical data until the online abstract release on November 11, 2021." Less than a month to go until CHM is allowed to release data. I have just moved a buy order up a bit. I am hoping that good news about "This abstract presentation will provide new information on the safety, efficacy, and bioactivity of CHM 1101 in patients treated at the initial low dose level of 44 X 106 cells with intratumoral administration in the ongoing phase 1 clinical trial." and "Abstract EXTH-10, to be presented on Friday November 19, will provide further insight into the mechanism by which CHM 1101 (CLTX CAR T) recognizes glioblastoma tumor cells. These novel findings continue to advance Chimeric’s understanding of the precise composition and localization of the cell surface complex recognized by CLTX CAR T." will start to create some interest around CHM. As I posted a little while ago, the top 20 holders now own just a bit over 68% of the company. So the SOI is very low. Add to this that any early signs of efficacy and safety, which will be discussed, will be guide posts towards a fast track approval pathway. Exciting times ahead.